Fresh from a decision by the Center for Medicare Services to establish national pricing for its VENDAJE allografts for regenerative therapies, BioStem Technologies (OTCQB:BSEM) is gearing up for a new spurt of growth.
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Tonix presents positive Phase 3 data in fibromyalgia
Tonix Pharmaceuticals (NASDAQ:TNXP) presented a poster at the 5th International Congress on Controversies in Fibromyalgia in Vienna that its TNX-102 SL met its pre-specified primary endpoint in the Phase 3 RELIEF trial...
Hepion expands SAB with appointments of four liver disease KOLs
Hepion Pharmaceuticals (NASDAQ:HEPA) added four new internationally recognized thought leaders to its scientific advisory board (SAB), effective immediately. These new members, who bring decades of liver disease...
Bolt posts positive Phase 1 data in HER2-expressing tumors
Bolt Biotherapeutics (NASDAQ:BOLT) reported positive topline data from its recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies. Topline...
Cognition presents proteomic biomarker data in Alzheimer’s
Cognition Therapeutics (NASDAQ:CGTX) presented results of a meta-analysis from the first cohort of 24 participants in the Phase 2 SHINE trial and the complete dataset from the Phase 1b SPARC studies in adults with mild...
STALICLA, Firefly to develop EEG as biomarker in autism
STALICLA SA and Firefly Neuroscience entered a partnership to further validate electroencephalogram (EEG)-based biomarkers in biologically enriched subgroups of patients with autism spectrum disorder (ASD). This follows...
NeuroSense, Mass General to collaborate on PrimeC in ALS
NeuroSense Therapeutics (NASDAQ:NRSN) signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, Ph.D., and Massachusetts General Hospital’s NeuroEpigenetics lab to explore the neurotherapeutic effects of...
OpSens names John Hannigan as CFO
OpSens (TSX:OPS; OTCQX:OPSSF) appointed John Hannigan as CFO, effective immediately. Mr. Hannigan is a highly experienced financial executive with more than 22 years of proven financial expertise with domestic and...
EyePoint completes enrollment in Phase 2 wet AMD trial
EyePoint Pharmaceuticals (NASDAQ:EYPT) completed enrollment in the Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance...
WB starts MDxHealth at outperform
William Blair launched coverage of MDxHealth S.A. (NASDAQ:MDXH) with an “outperform” rating. The stock closed at $2.86 on March 23. Analyst Andrew Brackmann writes that the rating is based on his belief that the company...
Vistagen posts positive Phase 3 open-label study of fasedienol in SAD
Vistagen (NASDAQ:VTGN) reported positive data from its Phase 3 open-label study designed to evaluate the safety and tolerability of multiple, as-needed intranasal administrations of fasedienol (PH94B) over time in...
Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial
Atossa Therapeutics (NASDAQ:ATOS) and Quantum Leap Healthcare Collaborative announced that Atossa’s proprietary selective estrogen receptor modulator, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I...
Hepion to highlight AI-POWR platform at AI webinar
Hepion Pharmaceuticals (NASDAQ:HEPA) will highlight its AI-POWR platform in a presentation during a webinar on March 23 entitled, “How Artificial Intelligence is Changing Drug Discovery.” The webinar is being co-hosted...
Just a few of the companies we’ve highlighted along the way
